NEW DELHI: Pune-based Gennova Biopharmaceuticals has filed an application alleging that German drug maker Boehringer Ingelheim had concealed important information when it approached the Delhi High Court late last month to stop the Indian company from launching its stroke medicine . Tenecteplase is prescribed globally to treat only heart attacks The affidavit in support of the PIL and the original affidavit filed by Boehringer were identical, said Nayar. According to Gennova's counsel, the PIL was filed at the behest of Boehringer and the German company approached the high court when it couldn't yield an interim order. There has to be an innovative drug with which you have to compare it," Chandhiok said.Justice Sanjeev Sachdeva, who was hearing the case, has directed that Boehringer's petition also be moved to the court hearing Das's PIL. The case is expected to be heard next by Chief Justice G Rohini and Justice Sangita Dhingra on September 20.

Source: Economic Times September 05, 2016 11:25 UTC